论文部分内容阅读
目的:观察分析前列地尔治疗高龄糖尿病并慢性肾脏病患者的临床疗效。方法:选取我院2012年7月~2014年8月收治的52例80岁以上糖尿病合并慢性肾脏病患者为研究对象,随机分为对照组与观察组。对照组基础治疗14d,后洗脱14d再注射10 g静推和基础治疗,1次/d,共14d;观察组在基础治疗的基础上给予前列地尔注射液10 g静推,1次/d,共14d,对比两组临床治疗效果。结果:所有患者经治疗后,与治疗前相比,ACR、CHOL、UAER及LDL-c均显著降低,(P<0.05)差异具有统计学意义;观察组患者UAER及ACR改善情况显著优于对照组,(P<0.05)差异具有统计学意义。结论:前列地尔用于治疗高龄糖尿病并慢性肾脏病患者疗效显著,可有效降低尿白蛋白,且安全性较高,值得临床广泛应用及推广。
Objective: To observe and analyze the clinical efficacy of alprostadil in the treatment of elderly patients with chronic kidney disease. Methods: Fifty-two patients with diabetes mellitus and chronic kidney disease over 80 years of age from July 2012 to August 2014 in our hospital were selected as study subjects and randomly divided into control group and observation group. In the control group, the rats in the control group were treated for 14 days, followed by elution for 14 days and then injected with 10 g of static push and basic treatment once per day for 14 days. The observation group was given 10 g of pirarubicin, d, a total of 14 days, compared with two groups of clinical treatment. Results: After treatment, ACR, CHOL, UAER and LDL-c in all patients were significantly lower than those before treatment (P <0.05), and the difference was statistically significant. The improvement of UAER and ACR in observation group was significantly better than that of control group Group, (P <0.05) the difference was statistically significant. Conclusion: Alprostadil is used to treat elderly patients with diabetes and chronic kidney disease with significant curative effect, which can effectively reduce urinary albumin and has high safety. It is worth widely clinical application and promotion.